haloalkane

(redirected from Hydrofluoroalkane)
Also found in: Dictionary, Thesaurus.

haloalkane

[¦ha·lō¦al‚kān]
(organic chemistry)
Halogenated aliphatic hydrocarbon.
McGraw-Hill Dictionary of Scientific & Technical Terms, 6E, Copyright © 2003 by The McGraw-Hill Companies, Inc.
Mentioned in ?
References in periodicals archive ?
Fluticasone propionate/salmeterol hydrofluoroalkane via metered-dose inhaler with integrated dose counter: performance and patient satisfaction.
3M's Plasma Coating Technology helps ensure technical success with inhalation components for hydrofluoroalkane (HFA) formulations by creating a layer that helps protect against degradation, deposition and corrosion.
Three hydrofluoroalkane (HFA)propelled albuterol inhalers have been approved by the FDA: Proair HFA Inhalation Aerosol, Proventil HFA Inhalation Aerosol, and Ventolin HFA Inhalation Aerosol.
Newer albuterol inhalers that use a hydrofluoroalkane (HFA) as a propellant instead of a CFC cost about $25-$30 more than CFC-containing inhalers, according to a review of the transition to newer albuterol inhalers (N.
The new report will help ensure FDA has an adequate scientific basis to review inhaler applications that use an alternative, hydrofluoroalkane.
In response to a federal push to remove chlorofluorocarbons (CFCs) from asthma inhalers by December 2008, some manufacturers have already stopped production of CFC-containing inhalers and are employing a new, more environmentally friendly propellant, hydrofluoroalkane. But the new inhalers are still in short supply, and drug stores are beginning to see a shortage.
Food and Drug Administration (FDA) approved Sepracor's New Drug Application (NDA) for XOPENEX HFA (hydrofluoroalkane) MDI (metered-dose inhaler) for the treatment or prevention of bronchospasm in adults, adolescents and children 4 years of age and older with reversible obstructive airway disease.
HFA (hydrofluoroalkane) propellants, safe for the environment, do not have any pharmacologic activity except at extremely high dosages.
The FDA approved Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, a hydrofluoroalkane metered-dose inhaler (MDI) for treatment or prevention of bronchospasm in adults, adolescents, and children at least 4 years old with reversible obstructive airway disease.
McElhattan et al., "Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial," Drugs, vol.
The company said that it will primarily use the funding to complete the Phase IIb clinical programme for its lead product, PT003, a combination bronchodilator comprised of glycopyrrolate, a long-acting muscarinic antagonist (LAMA), and formoterol, a well-known, long-acting B2-agonist (LABA), delivered via a hydrofluoroalkane metered dose inhaler (MDI) for the treatment of patients with COPD.